NCT05191667SuspendedPhase 1
An Open-Label Multicenter Phase Ib Study of AN0025 in Combination With Chemoradiotherapy in Patients With Locally Advanced/Locally Recurrent Esophageal Cancer
Adlai Nortye Biopharma Co., Ltd.1 site in 1 country32 target enrollmentStarted: January 18, 2022Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Suspended
- Enrollment
- 32
- Locations
- 1
- Primary Endpoint
- Number of participants with Dose Limiting Toxicities (DLTs)
Study Overview
Brief Summary
This is an open-label, multicenter, phase Ib study to evaluate the safety, tolerability, and preliminary efficacy of AN0025 in combination with chemoradiotherapy (CRT) in patients with locally advanced/locally recurrent esophageal cancer.
Detailed Description
This study will enroll patients with unresectable locally advanced/locally recurrent esophageal cancer or esophagogastric junction cancer to assess the safety and tolerability of AN0025 at 250mg QD and 500mg QD combined with concurrent chemoradiotherapy to fix the MTD or RP2D. At RP2D level, another 20 patients with unresectable locally advanced/locally recurrent esophageal cancer or esophagogastric junction cancer will be enrolled at PR2D dose level to explore the preliminary efficacy.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Diagnosed with histologically- and/or cytologically-confirmed locally advanced/locally recurrent squamous cell carcinoma or adenocarcinoma of the esophagus or of the esophagogastric junction (EGJ).
- •Male or female, age≥18 years at the time of informed consent.
- •Have provided signed informed consent for the trial and are willing to comply with all aspects of the protocol
Exclusion Criteria
- •With a history of another primary malignancy within the past 2 years, with the exception of basal or squamous cell skin cancer, or carcinoma in situ of the cervix or breast that has undergone potentially curative therapy.
- •Participants with known Hepatitis B or C infections, or known to be positive for Hepatitis B antigen (HBsAg)/ Hepatitis B virus (HBV) DNA or Hepatitis C antibody (HepC Ab)/ Hepatitis C virus (HCV) RNA. Active Hepatitis B is defined by a known positive HepB Ab result and known quantitative HBV DNA results greater than the lower limits of detection of the assay. Active Hepatitis C is defined by a known positive HepC Ab result and known quantitative HCV RNA results greater than the lower limits of detection of the assay.
- •Participants with known human immunodeficiency virus (HIV) infection (positive for HIV-1/2 antibody) or syphilis infection (positive for syphilis spiral antibody).
- •Major surgery or severe trauma within 4 weeks before the first dose of study drug. Note: If participant received major surgery, they must have recovered adequately from surgery and the toxicity and/or complications requiring the intervention prior to starting study treatment.
- •Have received prior systemic anti-cancer therapy including chemotherapy, target therapy, immunotherapy, anti-cancer traditional Chinese medicine, and other investigational oncology agents within 4 weeks or 5 half-lives, whichever is shorter. Participants who have entered the follow-up phase of an investigational study may participate as long as it has been at least 4 weeks (or 5 half-lives, whichever is shorter) after the last dose of the previous investigational agent.
- •Note: Participants must have recovered from all AEs due to previous therapies to ≤ Grade 1 or returned to baseline. Participants with ≤ Grade 2 neuropathy or alopecia (per CTCAE v5.0) may be eligible.
- •Are currently participating in a study of an investigational device within 4 prior to the first dose of study treatment.
- •Have uncontrolled tumor-related pain.
- •Have a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.
- •Have a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.
Arms & Interventions
Patients with unresectable locally advanced/locally recurrent esophageal cancer
Experimental
Patients will receive AN0025 orally once daily (QD) and chemoradiotherapy followed by the maintenance of AN0025
Intervention: AN0025 (Drug)
Outcomes
Primary Outcomes
Number of participants with Dose Limiting Toxicities (DLTs)
Time Frame: 4 weeks
DLTs are defined as study drug-related toxicities graded using Common Terminology Criteria for Adverse events of the National Cancer Institute (NCI CTCAE) V5.0 occurring during DLT period (the first 4 weeks of AN0025 administration in combination with dCRT)
Secondary Outcomes
- Overall survival (OS)(2 years)
- Complete response rate (CRR)(2 years)
- Objective response rate (ORR)(2 years)
- Progression-free survival (PFS)(2 years)
- Disease control rate (DCR)(2 years)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Active, not recruiting
Phase 1
AN0025 and Pembrolizumab Combination in Advanced Solid TumorsNSCLC, Squamous or Non-SquamousUrothelial Carcinoma of the BladderMicrosatellite Stable (MSS) Colorectal Cancer (CRC)Cervical CancerTriple-negative Breast CancerNCT04432857Adlai Nortye Biopharma Co., Ltd.63
Unknown
Phase 1
Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast CancerAdvanced Breast CancerNCT04856371Haihe Biopharma Co., Ltd.228
Unknown
Phase 1
JMT101 Combined With Afatinib in Patients With Advanced Esophageal Squamous Cell Carcinoma After Standard TherapyEsophageal Squamous CarcinomaNCT05164848Peking University50
Terminated
Phase 1
Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101Advanced Solid TumorsLymphomaNCT04144140Eisai Inc.24
Terminated
Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin LymphomaB-Cell LymphomaNon-Hodgkin LymphomaMultiple MyelomaNCT04045028Genentech, Inc.41